Onychomycosis, a fungal infection of the nail, is more common than you might think. In fact, it affects between 8 and 14 percent of North Americans. Beyond being unsightly, onychomycosis can be painful and uncomfortable, and it can significantly impact a person’s quality of life.
Fortunately, there are treatments available. One such treatment is Jublia (efinaconazole solution 10%), a topical antifungal medication designed to combat onychomycosis. Unlike oral medications, which can come with systemic side effects, Jublia offers a localized approach to tackling the infection.
But how effective is Jublia? This article dives into the heart of the matter, exploring the success rate of Jublia based on the data from clinical trials and long-term studies. We’ll examine both its efficacy and its safety profile, giving you a clearer picture of what to expect from this treatment option. So, just what is the success rate of Jublia?